News Releases

Year

Jan 28, 2020

Applied Therapeutics, Inc. Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares of Common Stock

NEW YORK , Jan. 28, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it has

Jan 23, 2020

Applied Therapeutics, Inc. Announces Upsizing and Pricing of Public Offering of 2,741,489 Shares of Common Stock

NEW YORK , Jan. 23, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the

Jan 21, 2020

Applied Therapeutics, Inc. Announces Offering of 1,750,000 Shares of Common Stock

NEW YORK , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it

Jan 08, 2020

Applied Therapeutics Announces Positive Topline Results of Pivotal Phase 2 ACTION-Galactosemia Study of AT-007 in Galactosemia Patients

AT-007 demonstrated a robust and sustained reduction in galactitol vs placebo; significant plasma galactitol reduction of ~50% (p